PL3562486T3 - Zastosowanie podjęzykowo deksmedetomidyny w leczeniu pobudzenia - Google Patents

Zastosowanie podjęzykowo deksmedetomidyny w leczeniu pobudzenia

Info

Publication number
PL3562486T3
PL3562486T3 PL17885750.4T PL17885750T PL3562486T3 PL 3562486 T3 PL3562486 T3 PL 3562486T3 PL 17885750 T PL17885750 T PL 17885750T PL 3562486 T3 PL3562486 T3 PL 3562486T3
Authority
PL
Poland
Prior art keywords
agitation
treatment
sublingual dexmedetomidine
dexmedetomidine
sublingual
Prior art date
Application number
PL17885750.4T
Other languages
English (en)
Inventor
Krishnan Nandabalan
Frank Yocca
Sameer Sharma
Original Assignee
Bioxcel Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioxcel Therapeutics, Inc. filed Critical Bioxcel Therapeutics, Inc.
Publication of PL3562486T3 publication Critical patent/PL3562486T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/4174Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
PL17885750.4T 2016-12-31 2017-12-29 Zastosowanie podjęzykowo deksmedetomidyny w leczeniu pobudzenia PL3562486T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662441164P 2016-12-31 2016-12-31
US201762471393P 2017-03-15 2017-03-15
US201762542323P 2017-08-08 2017-08-08
PCT/US2017/069030 WO2018126182A1 (en) 2016-12-31 2017-12-29 Use of sublingual dexmedetomidine for the treatment of agitation

Publications (1)

Publication Number Publication Date
PL3562486T3 true PL3562486T3 (pl) 2024-09-16

Family

ID=62710955

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17885750.4T PL3562486T3 (pl) 2016-12-31 2017-12-29 Zastosowanie podjęzykowo deksmedetomidyny w leczeniu pobudzenia

Country Status (19)

Country Link
US (7) US11839604B2 (pl)
EP (3) EP3562486B1 (pl)
JP (5) JP6868698B2 (pl)
KR (2) KR20190108104A (pl)
CN (1) CN110337290A (pl)
AU (3) AU2017388759B2 (pl)
BR (1) BR112019013503A2 (pl)
DK (1) DK3562486T3 (pl)
ES (1) ES2980126T3 (pl)
FI (1) FI3562486T3 (pl)
HU (1) HUE067266T2 (pl)
IL (1) IL267689B2 (pl)
MX (3) MX2019007923A (pl)
PL (1) PL3562486T3 (pl)
PT (1) PT3562486T (pl)
SG (1) SG10202107367SA (pl)
TW (3) TWI791479B (pl)
WO (1) WO2018126182A1 (pl)
ZA (1) ZA202006636B (pl)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3562486B1 (en) * 2016-12-31 2024-03-13 Bioxcel Therapeutics, Inc. Use of sublingual dexmedetomidine for the treatment of agitation
CN114983979A (zh) 2018-06-27 2022-09-02 比奥克斯塞尔医疗股份有限公司 含右美托咪定的膜制剂及其制造方法
EP3813828A4 (en) * 2018-06-27 2022-03-30 Bioxcel Therapeutics, Inc. METHOD OF TREATMENT OF AGITATION WITH DEXMEDETOMIDIN HYDROCHLORIDE
RU2692247C1 (ru) * 2018-12-06 2019-06-24 федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр имени В.А. Алмазова" Министерства здравоохранения Российской Федерации Способ лечения послеоперационного делирия
JP7739256B2 (ja) 2019-07-19 2025-09-16 バイオエクセル セラピューティクス,インコーポレイテッド 鎮静作用のないデクスメデトミジン治療レジメン
EP4031000A4 (en) * 2019-09-18 2023-09-27 Bioxcel Therapeutics, Inc. Systems and methods for detection and prevention of emergence of agitation
JP7412583B2 (ja) 2020-02-07 2024-01-12 ニューロヴェンティ カンパニー リミテッド リルメニジン化合物を有効成分として含む脆弱x症候群または関連発達障害を治療するための組成物
EP4104062A4 (en) * 2020-02-14 2024-04-24 Bioxcel Therapeutics, Inc. SYSTEMS AND METHODS FOR DETECTING AND PREVENTING THE APPEARANCE OF AGITATION
TW202228682A (zh) * 2020-10-08 2022-08-01 美商百歐克斯賽爾治療公司 使用右美托咪啶(dexmedetomidine)鹽酸鹽治療躁鬱症及精神病
TW202241416A (zh) * 2021-01-04 2022-11-01 美商百歐克斯賽爾治療公司 右美托咪啶(dexmedetomidine)治療方案
CA3208828A1 (en) * 2021-02-26 2022-09-01 Dinesh Kumar DHULL Methods and compositions for treating agitation
AU2022239873A1 (en) * 2021-03-19 2023-11-02 Orion Corporation Tasipimidine formulations and use thereof
WO2023278824A1 (en) * 2021-07-02 2023-01-05 Bioxcel Therapeutics, Inc. Methods for treating depressive states
GB2618810A (en) * 2022-05-17 2023-11-22 Novumgen Ltd Pharmaceutical composition for sublingual administration of clonidine
WO2024023261A1 (en) 2022-07-27 2024-02-01 Universität Zürich Dexmedetomidine for the treatment of sleep disorders
TW202421126A (zh) * 2022-09-11 2024-06-01 美商百歐克斯賽爾治療公司 治療在社區環境中躁動的方法
WO2024145347A1 (en) * 2022-12-27 2024-07-04 Alceptor Therapeutics, Inc. (s)-(3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl)methanol for treatment of agitation
US11806334B1 (en) 2023-01-12 2023-11-07 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens
WO2024263973A1 (en) * 2023-06-23 2024-12-26 Bioxcel Therapeutics, Inc. Dexmedetomidine treatment regimens
CN119139275B (zh) * 2024-11-05 2025-08-22 中国人民解放军军事科学院军事医学研究院 一种盐酸右美托咪定口溶膜及其制备方法和其应用

Family Cites Families (260)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8295A (en) 1851-08-12 Construction- of roofs
SU1138164A1 (ru) 1963-04-25 1985-02-07 Shadurskij Konstantin S Антигистаминное средство "димебон
US4407957A (en) 1981-03-13 1983-10-04 Damon Corporation Reversible microencapsulation of a core material
FI844786A0 (fi) 1984-12-04 1984-12-04 Farmos Oy Terapeutiskt utnyttjbar foerening.
US4839170A (en) 1985-10-01 1989-06-13 Survival Technology, Inc. Protein absorption enhancing agents
US4760093A (en) 1986-10-21 1988-07-26 American Home Products Corporation (Del.) Spray dried acetaminophen
US4767789A (en) 1986-10-21 1988-08-30 American Home Products Corporation (Del.) Spray dried acetaminophen
US4760094A (en) 1986-10-21 1988-07-26 American Home Products Corporation (Del.) Spray dried acetaminophen
US5039540A (en) 1989-08-14 1991-08-13 Neophore Technologies, Inc. Freeze dry composition and method for oral administration of drugs, biologicals, nutrients and foodstuffs
US5217718A (en) 1989-08-18 1993-06-08 Cygnus Therapeutic Systems Method and device for administering dexmedetomidine transdermally
US5178878A (en) 1989-10-02 1993-01-12 Cima Labs, Inc. Effervescent dosage form with microparticles
US5215756A (en) 1989-12-22 1993-06-01 Gole Dilip J Preparation of pharmaceutical and other matrix systems by solid-state dissolution
US5188825A (en) 1989-12-28 1993-02-23 Iles Martin C Freeze-dried dosage forms and methods for preparing the same
EP0585368B1 (en) 1991-04-25 1997-08-06 Brown University Research Foundation Implantable biocompatible immunoisolatory vehicle for delivery of selected therapeutic products
US5352456A (en) 1991-10-10 1994-10-04 Cygnus Therapeutic Systems Device for administering drug transdermally which provides an initial pulse of drug
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5569189A (en) 1992-09-28 1996-10-29 Equidyne Systems, Inc. hypodermic jet injector
DK0679088T3 (da) 1992-09-29 2002-10-28 Inhale Therapeutic Syst Pulmonal levering af aktive fragmenter af parathyreoideaea hormon
US5343672A (en) 1992-12-01 1994-09-06 Scherer Ltd R P Method for manufacturing freeze dried dosages in a multilaminate blister pack
US5631023A (en) 1993-07-09 1997-05-20 R.P. Scherer Corporation Method for making freeze dried drug dosage forms
GB2281206A (en) 1993-08-25 1995-03-01 Orion Yhtymae Oy Use of dexmedetomidine
US5457895A (en) 1993-10-01 1995-10-17 R. P. Scherer Corporation Method of identifying freeze-dried dosage forms
AU1330895A (en) 1993-11-29 1995-06-13 Adhesives Research, Inc. Water-soluble pressure sensitive adhesive
US5508367A (en) 1993-11-29 1996-04-16 Adhesives Research, Inc. Water-soluble pressure sensitive adhesive
US5395907A (en) 1993-11-29 1995-03-07 Adhesive Research, Inc. Water-soluble pressure sensitive adhesive
FR2718357B1 (fr) 1994-04-06 1997-10-03 Defarges Alain Moreau Perfectionnements apportés à un dispositif d'injection par jet sans aiguille.
GB2290964A (en) 1994-07-08 1996-01-17 Arto Olavi Urtti Transdermal drug delivery system
US5731387A (en) 1994-07-11 1998-03-24 Adhesives Research, Inc. Ionically-crosslinked water-absorbent graft copolymer
US5726250A (en) 1994-07-11 1998-03-10 Adhesives Research, Inc. Covalently crosslinked water-absorbent graft copolymer
US6726928B2 (en) 1994-10-28 2004-04-27 R.P. Scherer Technologies, Inc. Process for preparing solid dosage forms for unpalatable pharmaceuticals
GB9421836D0 (en) 1994-10-28 1994-12-14 Scherer Corp R P Process for preparing solid pharmaceutical dosage forms of hydrophobic substances
US5837287A (en) 1994-10-28 1998-11-17 R P Scherer Corporation Process for preparing solid pharmaceutical dosage forms
US5599302A (en) 1995-01-09 1997-02-04 Medi-Ject Corporation Medical injection system and method, gas spring thereof and launching device using gas spring
US5605911A (en) 1995-01-31 1997-02-25 Washington University Use of alpha-2 adrenergic drugs to prevent adverse effects of NMDA receptor hypofunction (NRH)
US5700873A (en) 1995-03-07 1997-12-23 Adhesives Research, Inc. Method of preparation of water-soluble copolymer
US5780014A (en) 1995-04-14 1998-07-14 Inhale Therapeutic Systems Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin
US5654007A (en) 1995-06-07 1997-08-05 Inhale Therapeutic Systems Methods and system for processing dispersible fine powders
GB9616672D0 (en) 1996-08-08 1996-09-25 Scherer Ltd R P Pharmaceutical compositions
US5800832A (en) 1996-10-18 1998-09-01 Virotex Corporation Bioerodable film for delivery of pharmaceutical compounds to mucosal surfaces
GB9700624D0 (en) 1997-01-14 1997-03-05 Danbiosyst Uk Drug delivery composition
GB9702799D0 (en) 1997-02-12 1997-04-02 Scherer Corp R P Process for preparing solid pharmaceutical dosage forms
ATE421318T1 (de) 1997-02-20 2009-02-15 Massachusetts Inst Technology Darreichungsform, welche rasche dispersionseigenschaften entfaltet, anwendungsverfahren sowie verfahren zur herstellung derselben
KR20000070375A (ko) 1997-02-21 2000-11-25 에드워드 엘. 데이지 압력 민감성 접착제 약물 경피 전달 시스템과 이에 사용되는압력 민감성 접착제
US6239228B1 (en) 1997-02-21 2001-05-29 Adhesives Research, Inc. Pressure sensitive adhesive containing macromer having repeat hydrophilic moieties
US5951999A (en) 1997-02-21 1999-09-14 Adhesives Research, Inc. Transdermal pressure sensitive adhesive drug delivery system
US6024981A (en) 1997-04-16 2000-02-15 Cima Labs Inc. Rapidly dissolving robust dosage form
US5976577A (en) 1997-07-11 1999-11-02 Rp Scherer Corporation Process for preparing fast dispersing solid oral dosage form
AU8977698A (en) 1997-07-25 1999-02-16 Elan Corporation, Plc A process for the preparation of a granulate suitable to the preparation of rapidly disintegrable mouth-soluble tablets
US7632517B2 (en) 1997-10-01 2009-12-15 Novadel Pharma Inc. Buccal, polar and non-polar spray containing zolpidem
GB9802088D0 (en) 1998-01-30 1998-03-25 Scherer Ltd R P Pharmaceutical products
PT1591360E (pt) 1998-03-09 2007-10-09 Cima Labs Inc ''aparelho para manusear e embalar comprimidos quebradiços''
US6200604B1 (en) 1998-03-27 2001-03-13 Cima Labs Inc. Sublingual buccal effervescent
US6716867B1 (en) 1998-04-01 2004-04-06 Orion Corporation Use of dexmedetomidine for ICU sedation
CA2334408C (en) 1998-06-03 2007-03-27 Scott Laboratories, Inc. Apparatus and method for providing a conscious patient relief from pain and anxiety associated with medical or surgical procedures
AU2005201500B2 (en) 1998-06-03 2007-01-04 Scott Laboratories, Inc. Apparatus and method for providing a conscious patient relief from pain and anxiety associated with medical or surgical procedures
US7565905B2 (en) 1998-06-03 2009-07-28 Scott Laboratories, Inc. Apparatuses and methods for automatically assessing and monitoring a patient's responsiveness
US7001609B1 (en) 1998-10-02 2006-02-21 Regents Of The University Of Minnesota Mucosal originated drug delivery systems and animal applications
BR9915738A (pt) 1998-11-20 2001-10-02 Rtp Pharma Inc Micropartìculas estabilizadas em fosfolipìdeos dispersìveis
GB9901819D0 (en) 1999-01-27 1999-03-17 Scherer Corp R P Pharmaceutical compositions
GB9908014D0 (en) 1999-04-08 1999-06-02 Scherer Corp R P Pharmaceutical compositions
US6284270B1 (en) 1999-08-04 2001-09-04 Drugtech Corporation Means for creating a mass having structural integrity
DE19940740A1 (de) 1999-08-31 2001-03-01 Gruenenthal Gmbh Pharmazeutische Salze
US6984207B1 (en) 1999-09-14 2006-01-10 Hoana Medical, Inc. Passive physiological monitoring (P2M) system
CA2324967A1 (en) 2000-11-01 2002-05-01 3816133 Canada Inc. System for monitoring patients with alzheimer's disease or related dementia
US6316029B1 (en) 2000-05-18 2001-11-13 Flak Pharma International, Ltd. Rapidly disintegrating solid oral dosage form
EP1299494B1 (en) 2000-07-07 2010-08-25 A.V. Topchiev Institute of Petrochemical Synthesis Preparation of hydrophilic pressure sensitive adhesives having optimized adhesive properties
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
US6814978B2 (en) 2000-12-29 2004-11-09 Mcneil-Ppc, Inc. Process for preparing a soft tablet
US20030022926A1 (en) 2001-05-07 2003-01-30 Lavand'homme Patricia Method for treating neuropathic pain and pharmaceutical preparation therefor
AU2002316146B2 (en) 2001-05-15 2007-09-06 Psychogenics Inc. Systems and methods for monitoring behaviour informatics
US6509040B1 (en) 2001-06-22 2003-01-21 R.P. Scherer Corporation Fast dispersing dosage forms essentially free of mammalian gelatin
AU2002334939A1 (en) 2001-10-12 2003-04-22 Eugene R. Cooper Compositions having a combination of particles for immediate release and for controlled release
US8765167B2 (en) 2001-10-12 2014-07-01 Monosol Rx, Llc Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US20140271788A1 (en) 2013-03-15 2014-09-18 Monosol Rx, Llc Sublingual and buccal film compositions
US8663687B2 (en) 2001-10-12 2014-03-04 Monosol Rx, Llc Film compositions for delivery of actives
US7357891B2 (en) 2001-10-12 2008-04-15 Monosol Rx, Llc Process for making an ingestible film
US8603514B2 (en) 2002-04-11 2013-12-10 Monosol Rx, Llc Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
US20070281003A1 (en) 2001-10-12 2007-12-06 Fuisz Richard C Polymer-Based Films and Drug Delivery Systems Made Therefrom
US7425292B2 (en) 2001-10-12 2008-09-16 Monosol Rx, Llc Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom
US7666337B2 (en) 2002-04-11 2010-02-23 Monosol Rx, Llc Polyethylene oxide-based films and drug delivery systems made therefrom
US8900498B2 (en) 2001-10-12 2014-12-02 Monosol Rx, Llc Process for manufacturing a resulting multi-layer pharmaceutical film
US20110033542A1 (en) 2009-08-07 2011-02-10 Monosol Rx, Llc Sublingual and buccal film compositions
FR2832311B1 (fr) 2001-11-21 2004-04-16 Besins Int Belgique Poudre filmogene, compositions la comprenant, leurs procedes de preparation et leurs utilisations
FR2834212B1 (fr) 2001-12-27 2004-07-09 Besins Int Belgique Utilisation d'une poudre a liberation immediate dans des compositions pharmaceutiques et nutraceutiques
CA2476250C (en) 2002-02-13 2010-08-03 Michael K. Weibel Drug dose-form and method of manufacture
BR0314540A (pt) 2002-10-08 2005-07-26 Allergan Inc Métodos para o tratamento de neurodegeneração
US20040156894A1 (en) 2003-02-07 2004-08-12 Grother Leon Paul Use of edible acids in fast-dispersing pharmaceutical solid dosage forms
EP3210601A1 (en) 2003-05-28 2017-08-30 MonoSolRX, LLC Polyethylene oxide-based films and drug delivery system made therefrom
US7282217B1 (en) 2003-08-29 2007-10-16 Kv Pharmaceutical Company Rapidly disintegrable tablets
JP4563393B2 (ja) 2003-10-24 2010-10-13 アドヒーシブズ・リサーチ・インコーポレイテッド 診断デバイス用崩壊性フィルム
US9248146B2 (en) 2003-10-24 2016-02-02 Adhesives Research, Inc. Dissolvable adhesive films for delivery of pharmaceutical or cosmetic agents
GB0403808D0 (en) 2004-02-20 2004-03-24 Bioprogress Technology Ltd Films for use as dosage forms
US20050222270A1 (en) 2004-02-26 2005-10-06 Olney John W Prolonged administration of NMDA antagonist drug and safener drug to create improved stable neural homeostasis
US7972621B2 (en) 2004-06-03 2011-07-05 R.P. Scherer Technologies, Llc Process for formulating fast dispersing dosage forms comprising at least one fish gelatin selected on the basis of molecular weight
US20060058590A1 (en) 2004-08-24 2006-03-16 Shaw Geoffrey M Method and system for assaying agitation
US20060058700A1 (en) 2004-08-26 2006-03-16 Marro Dominic P Patient sedation monitor
JP2008514612A (ja) 2004-09-23 2008-05-08 ミシャロウ、アレクサンダー 対抗適応を誘発することにより神経伝達物質系を調節する方法
EP1871219A4 (en) 2005-02-22 2011-06-01 Health Smart Ltd METHODS AND SYSTEMS FOR PSYCHOPHYSIOLOGICAL AND PHYSIOLOGICAL CONTROL AND USES THEREOF
EP1858515A2 (en) 2005-03-04 2007-11-28 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of anxiety disorders
US20090076156A1 (en) 2005-07-18 2009-03-19 Masud Husain Use of a noradrenergic agonist, e.g. guanfacine, for the treatment of cognitive disorders
US20070106126A1 (en) 2005-09-30 2007-05-10 Mannheimer Paul D Patient monitoring alarm escalation system and method
CA2624731A1 (en) 2005-10-04 2007-04-12 Medivation, Inc. Hydrogenated pyrido-indole compounds for the treatment of huntington's disease
US8158152B2 (en) 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
WO2007074472A2 (en) 2005-12-27 2007-07-05 Jubilant Organosys Limited Mouth dissolving pharmaceutical composition and process for preparing the same using a high amount of silicon dioxide
DK1986642T3 (da) 2006-02-13 2014-02-03 Orient Pharma Samoa Co Ltd Kombination af alfa-2-receptoragonist (clonidin) og et antimuscarinmiddel (oxybutynin) til behandling af sialorrhoea
US7630758B2 (en) 2006-06-22 2009-12-08 General Electric Company Separation of natural and drug-induced sleep of a subject
US20080026040A1 (en) 2006-07-31 2008-01-31 Isaac Farr Active agent-releasing dosage forms
JP4739452B2 (ja) 2006-09-20 2011-08-03 モノソル アールエックス リミテッド ライアビリティ カンパニー 発泡を減じる風味付与剤を含む喫食可能な水溶性フィルム
US8157730B2 (en) 2006-12-19 2012-04-17 Valencell, Inc. Physiological and environmental monitoring systems and methods
US20080153808A1 (en) 2006-12-22 2008-06-26 Allergan, Inc. Alpha-2 receptor pan agonist and serotonin-norepinephrine reuptake inhibitor compositions for treating chronic pain
US20100028447A1 (en) 2007-01-22 2010-02-04 Targacept, Inc. Intranasal, Buccal, And Sublingual Administration Of Metanicotine Analogs
US8568777B2 (en) 2007-03-30 2013-10-29 Monosol Rx, Llc Packaged film dosage unit containing a complexate
WO2008141264A1 (en) 2007-05-10 2008-11-20 Novadel Pharma Inc. Anti-insomnia compositions and methods
US20090099480A1 (en) 2007-05-24 2009-04-16 Peter Salgo System and method for patient monitoring
WO2009002084A2 (en) 2007-06-27 2008-12-31 Hanmi Pharm. Co., Ltd. Method for preparing rapidly disintegrating formulation for oral administration and apparatus for preparing and packing the same
RU2338533C1 (ru) 2007-06-28 2008-11-20 Сергей Олегович Бачурин СРЕДСТВО, ОБЛАДАЮЩЕЕ АНКСИОЛИТИЧЕСКИМ ДЕЙСТВИЕМ, НА ОСНОВЕ ГИДРИРОВАННЫХ ПИРИДО(4,3-b)ИНДОЛОВ (ВАРИАНТЫ), ФАРМАКОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ И СПОСОБ ЕГО ПРИМЕНЕНИЯ
JP2010535220A (ja) 2007-08-01 2010-11-18 メディベイション ニューロロジー, インコーポレイテッド 抗精神病用の併用療法剤を使用する統合失調症の治療のための方法および組成物
AU2008311350B2 (en) 2007-10-11 2014-04-03 Philip Morris Products S.A. Smokeless tobacco product
US8298583B2 (en) 2007-10-19 2012-10-30 Monosol Rx, Llc Film delivery system for tetrahydrolipstatin
PE20091084A1 (es) 2007-12-07 2009-07-23 Schering Plough Healthcare Formulaciones farmaceuticas de fenilefrina y composiciones para absorcion transmucosal
CN101496801A (zh) 2008-02-02 2009-08-05 四川百利药业有限责任公司 右旋美托咪定及其药用盐的用途
PL2252290T3 (pl) 2008-02-15 2018-06-29 Bone Therapeutics S.A. Kompozycja farmaceutyczna do zastosowania w leczeniu i/lub zapobieganiu chorobom kostno-stawowym
MY173867A (en) 2008-02-28 2020-02-25 Scherer Technologies Llc R P Process to minimize polymorphism
US20190216389A1 (en) 2008-04-07 2019-07-18 Christopher Scheib Method and system for analyzing a series of electroencephalogram (eeg) signals during altered brain states
US20090275853A1 (en) 2008-04-30 2009-11-05 The General Electric Company Method and apparatus for monitoring physiological state of a subject
US8882684B2 (en) 2008-05-12 2014-11-11 Earlysense Ltd. Monitoring, predicting and treating clinical episodes
US20100029706A1 (en) 2008-07-30 2010-02-04 Edison Parmaceuticals, Inc. a Delaware Corporation HYDROGENATED PYRIDO[4,3-b]INDOLES FOR THE TREATMENT OF OXIDATIVE STRESS
US20110172262A1 (en) 2008-09-15 2011-07-14 Biovista, Inc. Compositions and methods for treating epilepsy
US8485861B2 (en) 2008-10-31 2013-07-16 The Invention Science Fund I, Llc Systems, devices, and methods for making or administering frozen particles
US8603496B2 (en) 2008-10-31 2013-12-10 The Invention Science Fund I, Llc Compositions and methods for biological remodeling with frozen particle compositions
US8470546B2 (en) 2008-11-25 2013-06-25 Albert Einstein College Of Medicine Of Yeshiva University Treatment of autism spectrum disorders with agents that activate the Locus Coeruleus-Noradrenergic system
US20100196286A1 (en) 2008-12-01 2010-08-05 Armer Thomas A Inhalation delivery methods and devices
US8282954B2 (en) 2008-12-15 2012-10-09 Monosol Rx, Llc Method for manufacturing edible film
TR200903014A1 (tr) 2009-04-17 2010-11-22 Sanovel İlaç San. Ve Ti̇c. A.Ş. Oral yolla dağılan dimebolin bileşimleri.
RU2572692C2 (ru) 2009-05-15 2016-01-20 Рекро Фарма, Инк. Сублингвальные композиции дексмедетомидина и способы их применения
US8475832B2 (en) 2009-08-07 2013-07-02 Rb Pharmaceuticals Limited Sublingual and buccal film compositions
US9775819B2 (en) 2009-09-16 2017-10-03 R.P. Scherer Technologies, Llc Oral solid dosage form containing nanoparticles and process of formulating the same using fish gelatin
US8313768B2 (en) 2009-09-24 2012-11-20 Mcneil-Ppc, Inc. Manufacture of tablet having immediate release region and sustained release region
WO2011039686A1 (en) 2009-09-30 2011-04-07 Pfizer Inc. Latrepirdine oral sustained release dosage forms
CN102753169A (zh) 2010-01-08 2012-10-24 瑞克欧制药有限公司 外用透皮右美托咪啶组合物及其应用方法
WO2011109716A2 (en) 2010-03-04 2011-09-09 Neumitra LLC Devices and methods for treating psychological disorders
US10548839B2 (en) 2010-03-16 2020-02-04 Wei Tian Process of manufacturing a lyophilized fast dissolving, multi-phasic dosage form
US20130029989A1 (en) 2010-04-15 2013-01-31 The Royal Institution For The Advancement Of Learning/Mcgill University Topical treatments for pain
US9572773B2 (en) 2010-04-26 2017-02-21 Novartis A.G. Layered drug delivery device
US20110290694A1 (en) 2010-05-27 2011-12-01 Monosol Rx, Llc Oral film dosage form having indicia thereon
US8529914B2 (en) 2010-06-28 2013-09-10 Richard C. Fuisz Bioactive dose having containing a material for modulating pH of a bodily fluid to help or hinder absorption of a bioactive
WO2012024106A2 (en) 2010-08-17 2012-02-23 University Of Florida Research Foundation, Inc. Central site photoplethysmography, medication administration, and safety
KR101802553B1 (ko) 2010-09-23 2017-11-28 모노졸 알엑스, 엘엘씨 제약 생성물을 패키지 표면 상에 직접적으로 형성시키는 방법 및 시스템
US8383135B2 (en) 2010-12-03 2013-02-26 Richard C. Fuisz Solid dosage form that promotes reliable oral, esophageal and GI transit
KR102161392B1 (ko) 2010-12-16 2020-10-05 선오비온 파마슈티컬스 인코포레이티드 설하 필름
US20140163080A1 (en) 2011-02-03 2014-06-12 Gnt, Llc Compositions and Methods for Treatment of Glaucoma
WO2012104834A1 (en) 2011-02-03 2012-08-09 Pharmedica Ltd. New oral dissolving films for insulin administration, for treating diabetes
US8445526B2 (en) 2011-02-03 2013-05-21 Glaucoma & Nasal Therapies Llc Compositions and methods for treatment of glaucoma
US8703697B2 (en) 2011-06-24 2014-04-22 Luc QUINTIN Method for treating early severe diffuse acute respiratory distress syndrome
US8241661B1 (en) 2011-06-24 2012-08-14 Fuisz Richard C Biocompatible film with variable cross-sectional properties
US20130096170A1 (en) 2011-10-14 2013-04-18 Hospira, Inc. Methods of treating pediatric patients using dexmedetomidine
WO2013061161A2 (en) 2011-10-28 2013-05-02 Green Bcn Consulting Services Sl New combination therapies for treating neurological disorders
CA2858721C (en) 2011-12-11 2021-03-16 Recro Pharma, Inc. Intranasal dexmedetomidine compositions and methods of use thereof
US8242158B1 (en) 2012-01-04 2012-08-14 Hospira, Inc. Dexmedetomidine premix formulation
WO2013130577A2 (en) 2012-02-27 2013-09-06 Eye Therapies, Llc Compositions and methods for the treatment of migraine
JP5921928B2 (ja) 2012-03-28 2016-05-24 テルモ株式会社 既希釈デクスメデトミジン製剤
CN102657635B (zh) 2012-05-04 2013-08-07 上海现代药物制剂工程研究中心有限公司 具有微孔的海绵状的阿塞那平舌下膜剂及其制备方法
WO2013173317A1 (en) 2012-05-14 2013-11-21 Prospire, Llc TREATMENT OF OBSTRUCTIVE SLEEP APNEA WITH α2-ADRENERGIC RECEPTOR AGONISTS
CN104684548A (zh) 2012-07-06 2015-06-03 埃格勒特有限责任公司 防止滥用的控释药物组合物
US10130766B1 (en) 2012-08-08 2018-11-20 Neurowave Systems Inc. Intelligent pharmaceutical delivery system with automatic shutoff and method of using
EP2719376B1 (en) 2012-10-12 2015-03-04 Omya International AG Gastroretentive drug formulation and delivery systems and their method of preparation using functionalized calcium carbonate
US20140180160A1 (en) 2012-10-12 2014-06-26 Emery N. Brown System and method for monitoring and controlling a state of a patient during and after administration of anesthetic compound
PL2906213T3 (pl) * 2012-10-15 2018-04-30 Orion Corporation Weterynaryjny sposób łagodzenia awersji wobec hałasu
GB2510321B (en) 2012-11-12 2018-01-31 Biosurgical S L Agitation apparatus
US9545376B2 (en) 2013-01-23 2017-01-17 Arx, Llc Production of unit dose constructs
WO2014130777A1 (en) * 2013-02-21 2014-08-28 University Of Rochester Methods for evaluating brain-wide paravascular pathway for waste clearance function and methods for treating neurodegenerative disorders based thereon
US20140328898A1 (en) 2013-03-15 2014-11-06 Children's National Medical Center Nano-Liposomal Formulations and Methods of Use
US9346601B2 (en) 2013-03-15 2016-05-24 Monosol Rx, Llc Reduction in stress cracking of films
US20140261990A1 (en) 2013-03-15 2014-09-18 Monosol Rx, Llc Multi-layer films having uniform content
US9303918B2 (en) 2013-03-15 2016-04-05 Monosol Rx, Llc Process for drying a wet film with control of loss on drying
WO2014153489A1 (en) 2013-03-22 2014-09-25 Adhesives Research, Inc. Hydrophilic adhesives and tapes and devices containing the same
US20140316217A1 (en) 2013-04-23 2014-10-23 Patrick L. Purdon System and method for monitoring anesthesia and sedation using measures of brain coherence and synchrony
US20140323897A1 (en) 2013-04-24 2014-10-30 Emery N. Brown System and method for estimating high time-frequency resolution eeg spectrograms to monitor patient state
US20140323898A1 (en) 2013-04-24 2014-10-30 Patrick L. Purdon System and Method for Monitoring Level of Dexmedatomidine-Induced Sedation
CN103284945A (zh) 2013-06-03 2013-09-11 四川百利药业有限责任公司 一种预充式盐酸右美托咪定注射液的制备方法
JP6453319B2 (ja) 2013-06-04 2019-01-16 モノソル リミテッド ライアビリティ カンパニー 水溶性フィルムシール溶液、関連する方法、および関連する物品
EP3014290A4 (en) 2013-06-27 2017-03-08 The General Hospital Corporation Systems and methods for tracking non-stationary spectral structure and dynamics in physiological data
WO2014210527A1 (en) 2013-06-28 2014-12-31 The General Hospital Corporation System and method to infer brain state during burst suppression
US10602978B2 (en) 2013-09-13 2020-03-31 The General Hospital Corporation Systems and methods for improved brain monitoring during general anesthesia and sedation
ES2983565T3 (es) 2013-10-07 2024-10-23 Teikoku Pharma Usa Inc Métodos y composiciones para tratar los síndromes de abstinencia mediante el uso de composiciones transdérmicas de dexmedetomidina no sedantes
BR112016006848A2 (pt) * 2013-10-07 2017-08-01 Teikoku Pharma Usa Inc métodos e composições para distribuição transdérmica de uma quantidade não sedativa de dexmedetomidina
WO2015054062A2 (en) 2013-10-07 2015-04-16 Teikoku Pharma Usa, Inc. Methods and compositions for managing pain comprising dexmedetomidine transdermal compositions
EP3054932B1 (en) 2013-10-07 2020-12-09 Teikoku Pharma USA, Inc. Dexmedetomidine transdermal delivery devices and methods for using the same
TWI709417B (zh) 2013-10-07 2020-11-11 美商帝國製藥美國股份有限公司 使用右美托咪啶經皮組成物用於治療注意力不足過動症、焦慮及失眠的方法及組成物
WO2015069778A1 (en) 2013-11-05 2015-05-14 The General Hospital Corporation System and method for determining neural states from physiological measurements
US11033493B2 (en) 2013-12-02 2021-06-15 Intelgenx Corp. Film dosage form with extended release mucoadhesive particles
US9974754B2 (en) 2013-12-18 2018-05-22 Maruishi Pharmaceutical Co., Ltd. Hydrous adhesive patch
US20170231556A1 (en) 2014-08-22 2017-08-17 The General Hospital Corporation Systems and methods for predicting arousal to consciousness during general anesthesia and sedation
US20170274174A1 (en) 2014-08-22 2017-09-28 The General Hospital Corporation System and method for administering, monitoring and controlling biomimetic sleep
WO2016029211A1 (en) 2014-08-22 2016-02-25 The General Hospital Corporation Systems and methods for discovery and characterization of neuroactive drugs
US9726337B2 (en) * 2014-08-27 2017-08-08 R. W. Swarens Associates, Inc. Light fixture for indirect asymmetric illumination with LEDs
CN104161760A (zh) 2014-09-01 2014-11-26 西北农林科技大学 一种貉用复合麻醉剂及其制备方法和应用
MA41689A (fr) 2014-10-15 2017-08-22 Bioxcel Corp Prévention ou traitement de troubles du sommeil au moyen d'une formulation de dexmédétomidine
WO2016061554A1 (en) * 2014-10-16 2016-04-21 Bioxcel Corporation Synergistic composition of known, safe pharmaceuticals for use in insomnia and a method of treatment thereof
FI127534B (en) 2014-11-10 2018-08-31 Vetcare Oy Substituted benzoefuroquinolizine and ɑ2-adrenergic agonist comprising compositions
US10022341B2 (en) 2014-12-02 2018-07-17 Yale University Methods of preventing neurodegeneration of association cortex in a mammal
JP2016154598A (ja) 2015-02-23 2016-09-01 ニプロ株式会社 デクスメデトミジン注射液を充填したプレフィルドシリンジ
CN104784174A (zh) 2015-03-06 2015-07-22 北京大学第一医院 右美托咪定的药物新用途
WO2016164903A1 (en) 2015-04-10 2016-10-13 Hemcon Medical Technologies, Inc. Bioadhesive chitosan gel for controlling bleeding and for promoting healing with scar reduction without obscuring or interfering with access to a surgical field
CN106038538A (zh) 2015-04-17 2016-10-26 江苏恒瑞医药股份有限公司 一种右美托咪定的预混合制剂
US10179136B2 (en) 2015-06-19 2019-01-15 Imprimis Pharmaceuticals, Inc. Pharmaceutical compositions and methods for anesthesiological applications
US20160374588A1 (en) 2015-06-24 2016-12-29 Microsoft Technology Licensing, Llc Monitoring hydration based on galvanic skin response
CN105168122B (zh) 2015-09-24 2018-11-27 辰欣药业股份有限公司 一种盐酸右美托咪定注射液及其制备工艺
US20170128421A1 (en) 2015-11-11 2017-05-11 Siva Prasad Reddy Sura Premix formulation for parenteral use and packaging thereof
US10632043B2 (en) 2015-11-11 2020-04-28 Aurobindo Pharma Ltd Premix formulation for parenteral use and packaging thereof
CA3009697C (en) 2016-01-04 2024-05-28 Jurox Pty Ltd Drug release device and use
CN105534891A (zh) 2016-01-18 2016-05-04 南京正科医药股份有限公司 一种盐酸右美托咪定注射液
US9949934B1 (en) 2016-10-20 2018-04-24 Intelgenx Corp. Device and method of treating conditions associated with neuroinflammation
US9717796B1 (en) 2016-04-20 2017-08-01 Slypharma, Llc Heat sterilizeable, premixed, ready to use dexmedetomidine solution packaged in a flexible plastic container
CN107412152B (zh) 2016-05-24 2020-12-04 海南合瑞制药股份有限公司 一种盐酸右美托咪定注射液组合物
WO2017213977A1 (en) 2016-06-07 2017-12-14 Mehra Akhil Methods and compositions for the treatment of trauma and stressor-related disorders
CN105997955B (zh) 2016-06-28 2017-09-12 力品药业(厦门)有限公司 一种帕洛诺司琼口腔膜剂及其制备方法
RU2635532C1 (ru) 2016-09-06 2017-11-13 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации Способ профилактики ажитационного синдрома у детей с онкологической патологией
CN115089547A (zh) 2016-10-12 2022-09-23 Ps治疗有限公司 人工泪液、隐形眼镜和药物载体组合物及其使用方法
US11026883B2 (en) 2016-10-13 2021-06-08 Catalent U.K. Swindon Zydis Limited Lyophilized pharmaceutical compositions for vaginal delivery
JP6968184B2 (ja) 2016-10-25 2021-11-17 キャタレント・ユーケー・スウィンドン・ザイディス・リミテッド 速崩壊多層錠のための異なる密度の組成物
CN110022865A (zh) 2016-10-31 2019-07-16 帝国制药美国公司 使用右美托咪定经皮递送装置管理疼痛的方法
WO2018081792A2 (en) 2016-10-31 2018-05-03 Allodynic Therapeutics, Llc Combinations of opioid/tlr4 antagonists and acetaminophen for use in the treatment of emotional pain and insomnia
CN106727524A (zh) 2016-11-08 2017-05-31 叶茂 一种药物组合物及其应用
CN106539778A (zh) 2016-12-08 2017-03-29 武汉大学 一种小儿麻醉术前含服口腔泡腾片及其制备方法
CN106727443A (zh) 2016-12-08 2017-05-31 武汉大学 一种小儿麻醉术前镇静的隐形鼻贴制剂及其制备方法
DK3554501T3 (da) 2016-12-13 2021-07-19 Orion Corp Dexmedetomidin eller medetomidin til anvendelse i behandling af separationsangst hos kæledyr
WO2018116202A1 (en) 2016-12-20 2018-06-28 Azista Industries Pvt Ltd Stabilized mouth freshener strips
EP3562486B1 (en) * 2016-12-31 2024-03-13 Bioxcel Therapeutics, Inc. Use of sublingual dexmedetomidine for the treatment of agitation
JP2020510675A (ja) 2017-03-07 2020-04-09 チャイルズ, マークCHILDS, Marc ミトコンドリア起源のrosの産生の特異的阻害剤を使用した、薬物誘発qt間隔延長に関連するリスクの予防
CN107137399A (zh) 2017-04-24 2017-09-08 徐颖 一种用于麻醉的舌下片及其制备方法
CN107693485A (zh) 2017-04-24 2018-02-16 重庆医科大学附属儿童医院 一种用于麻醉的滴鼻液及其制备方法
CN107412204A (zh) 2017-04-24 2017-12-01 重庆医科大学附属儿童医院 一种用于麻醉的干粉吸入剂及其制备方法
CN107028880A (zh) 2017-06-09 2017-08-11 安徽赛诺制药有限公司 一种盐酸右美托咪定注射液的生产工艺
US20200368352A1 (en) 2017-08-15 2020-11-26 The Board Of Trustees Of The Leland Stanford Junior University Polymeric perfluorocarbon nanoemulsions for ultrasonic drug uncaging
EP3668490A4 (en) 2017-08-20 2021-06-09 Formulex Pharma Innovations Ltd. Dry powder compositions for intranasal delivery
US11857334B2 (en) 2017-10-04 2024-01-02 The General Hospital Corporation Systems and methods for monitoring a subject under the influence of drugs
US20190216345A1 (en) 2017-10-18 2019-07-18 Christoper Scheib Method and system for monitoring and displaying physiological conditions
US11147459B2 (en) 2018-01-05 2021-10-19 CareBand Inc. Wearable electronic device and system for tracking location and identifying changes in salient indicators of patient health
US11406316B2 (en) 2018-02-14 2022-08-09 Cerenion Oy Apparatus and method for electroencephalographic measurement
US10988638B2 (en) 2018-03-08 2021-04-27 Catalent U.K. Swindon Zydis Limited Process to reduce endotoxin in gelatin
KR20190109310A (ko) 2018-03-15 2019-09-25 주식회사 바이오홀딩스 레반을 함유하는 염증성 질환 치료용 경비투여형 스프레이 제제
CN108498469A (zh) 2018-05-30 2018-09-07 宁波蒙曼生物科技有限公司 盐酸右美托咪定冻干粉及其制备方法
CN114983979A (zh) 2018-06-27 2022-09-02 比奥克斯塞尔医疗股份有限公司 含右美托咪定的膜制剂及其制造方法
EP3813828A4 (en) 2018-06-27 2022-03-30 Bioxcel Therapeutics, Inc. METHOD OF TREATMENT OF AGITATION WITH DEXMEDETOMIDIN HYDROCHLORIDE
CA3105187A1 (en) 2018-06-28 2020-01-02 Arx, Llc Dispensing method for producing dissolvable unit dose film constructs
CN110893186A (zh) 2018-09-12 2020-03-20 宜昌人福药业有限责任公司 一种药物组合物及其制备方法和用途
JP2019048091A (ja) 2018-10-23 2019-03-28 ニプロ株式会社 デクスメデトミジン注射液を充填したプレフィルドシリンジ
KR102183744B1 (ko) 2018-11-26 2020-11-27 연세대학교 산학협력단 섬망 발병 위험도의 예측 방법 및 이를 이용한 디바이스
CN109620802A (zh) 2018-12-05 2019-04-16 杜皓 一种麻醉用鼻喷剂及其制备方法
CN111481506B (zh) 2019-01-25 2023-01-24 江苏恒瑞医药股份有限公司 一种包含经鼻给药的右美托咪定组合物的药物制品
US10900762B2 (en) 2019-02-21 2021-01-26 Aob Products Company Ammunition press and components thereof
WO2020259440A1 (zh) 2019-06-28 2020-12-30 四川普锐特药业有限公司 右美托咪定鼻喷剂、其制备方法及应用
CN116474219A (zh) 2019-06-28 2023-07-25 四川普锐特药业有限公司 保持给药均一度的药物流体分配器及右美托咪定鼻喷器
JP7739256B2 (ja) 2019-07-19 2025-09-16 バイオエクセル セラピューティクス,インコーポレイテッド 鎮静作用のないデクスメデトミジン治療レジメン
EP4031000A4 (en) 2019-09-18 2023-09-27 Bioxcel Therapeutics, Inc. Systems and methods for detection and prevention of emergence of agitation
EP4104062A4 (en) 2020-02-14 2024-04-24 Bioxcel Therapeutics, Inc. SYSTEMS AND METHODS FOR DETECTING AND PREVENTING THE APPEARANCE OF AGITATION
TW202228682A (zh) 2020-10-08 2022-08-01 美商百歐克斯賽爾治療公司 使用右美托咪啶(dexmedetomidine)鹽酸鹽治療躁鬱症及精神病
TW202241416A (zh) 2021-01-04 2022-11-01 美商百歐克斯賽爾治療公司 右美托咪啶(dexmedetomidine)治療方案
CA3208828A1 (en) 2021-02-26 2022-09-01 Dinesh Kumar DHULL Methods and compositions for treating agitation

Also Published As

Publication number Publication date
HUE067266T2 (hu) 2024-10-28
SG10202107367SA (en) 2021-08-30
US20230081503A1 (en) 2023-03-16
TWI791479B (zh) 2023-02-11
JP6868698B2 (ja) 2021-05-12
CA3045043A1 (en) 2018-07-05
ZA202006636B (en) 2023-03-29
TW201829018A (zh) 2018-08-16
PT3562486T (pt) 2024-06-12
IL267689A (en) 2019-08-29
DK3562486T3 (da) 2024-06-10
TW202423422A (zh) 2024-06-16
TW202319048A (zh) 2023-05-16
AU2017388759B2 (en) 2021-11-11
IL267689B1 (en) 2025-01-01
EP4371554A2 (en) 2024-05-22
TWI833550B (zh) 2024-02-21
US20230093109A1 (en) 2023-03-23
EP4368169A3 (en) 2024-08-07
JP2021102654A (ja) 2021-07-15
US11839604B2 (en) 2023-12-12
EP3562486A1 (en) 2019-11-06
FI3562486T3 (fi) 2024-06-04
EP3562486A4 (en) 2020-08-19
IL267689B2 (en) 2025-05-01
JP2020503323A (ja) 2020-01-30
AU2022200892B2 (en) 2024-06-13
EP4368169A2 (en) 2024-05-15
AU2024219731A1 (en) 2024-10-10
CN110337290A (zh) 2019-10-15
US20240252470A1 (en) 2024-08-01
MX2023000213A (es) 2023-02-09
BR112019013503A2 (pt) 2020-01-07
JP2021113203A (ja) 2021-08-05
JP2022040229A (ja) 2022-03-10
EP4371554A3 (en) 2024-08-07
KR102793584B1 (ko) 2025-04-09
JP6929479B2 (ja) 2021-09-01
US11786508B2 (en) 2023-10-17
JP7008153B2 (ja) 2022-02-10
US20230218580A1 (en) 2023-07-13
MX2019007923A (es) 2019-09-10
AU2022200892A1 (en) 2022-03-03
JP2024014900A (ja) 2024-02-01
AU2017388759A1 (en) 2019-06-13
MX2022010274A (es) 2022-09-19
ES2980126T3 (es) 2024-09-30
EP3562486B1 (en) 2024-03-13
US20190365715A1 (en) 2019-12-05
US20220031663A1 (en) 2022-02-03
WO2018126182A1 (en) 2018-07-05
US20250325521A1 (en) 2025-10-23
KR20190108104A (ko) 2019-09-23
US11931340B2 (en) 2024-03-19
KR20240031326A (ko) 2024-03-07

Similar Documents

Publication Publication Date Title
ZA202006636B (en) Use of sublingual dexmedetomidine for the treatment of agitation
IL275482A (en) Asketamine for the treatment of depression
ZA201707303B (en) Compositions and methods for the treatment of immunodeficiency
SI3261726T1 (sl) Sestavek za zdravljenje aken
GB201400442D0 (en) Compositions for use in the treatment of ulcerative colitis
AP2016009497A0 (en) Process for the treatment of high sulphate waters
HUS2400045I1 (hu) Delgocitinib alkalmazása krónikus kézekcéma kezelésére
PT3122349T (pt) Composições para o tratamento da autodigestão
EP3145525A4 (en) Use of microperoxidases for the treatment of carboxyhemoglobinemia
PT3548006T (pt) Composição para utilização no tratamento de alterações intestinais
IL252493A0 (en) Compounds for use in the prevention or treatment of cancer
IL267059A (en) A preparation for the treatment of osteoarthritis
ZA201703047B (en) The treatment of water
ZA201704589B (en) Compounds for the treatment of cancer
PL3273997T3 (pl) Kompozycja do leczenia nieżytu nosa
GB201701928D0 (en) Compounds for the treatment of hyperglycaemia
PT3524255T (pt) Composição para o tratamento do acne
GB201603752D0 (en) Treatment of hypothyroidism
GB201603755D0 (en) Treatment of hypothyroidism
ZA201503312B (en) The treatment of waste water
PL3206701T3 (pl) Canephron do leczenia zapalenia gruczołu krokowego
GB201412270D0 (en) Finishing treatment